Matrix Private Capital Group’s Bio-Rad Laboratories Class A BIO Stock Holding History

Matrix Private Capital Group’s Portfolio BIO Stock Details BIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-307	Closed	-$232K	–	258
2021 Q4	$232K	Sell	307 -1	-0.3%	-$748	0.11%	167
2021 Q3	$230K	Sell	308 -74	-19%	-$55.4K	0.12%	155
2021 Q2	$246K	Hold	382	–	–	0.13%	149
2021 Q1	$218K	Buy	382 +5	+1%	+$2.96K	0.13%	160
2020 Q4	$220K	Buy	+377	New	+$215K	0.16%	143

Other funds holding BIO

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

Brown Advisory Baltimore, Maryland $64.6B AUM 18.98% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Matrix Private Capital Group's BIO Position: Q1 2022 in Review

Matrix Private Capital Group sold out of Bio-Rad Laboratories Class A (BIO) in Q1 2022, closing a stake of 307 shares — an estimated $232K sold.

Matrix Private Capital Group first reported a position in BIO in Q4 2020 and held it in 5 quarters. The position peaked at $246K in Q2 2021. 514 funds tracked by Wall St. Rank hold BIO as of Q1 2022.

Matrix Private Capital Group reported no remaining Bio-Rad Laboratories Class A position as of Q1 2022 after selling out during the quarter.
Matrix Private Capital Group sold 307 Bio-Rad Laboratories Class A shares in Q1 2022, an estimated $232K.
Matrix Private Capital Group first reported a position in Bio-Rad Laboratories Class A in Q4 2020 and held it in 5 quarters.
Matrix Private Capital Group's Bio-Rad Laboratories Class A position peaked at $246K in Q2 2021.
514 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q1 2022.

Based on Matrix Private Capital Group's 13F filing for Q1 2022, filed 16 May 2022.